Chinese company at the forefront of cancer prevention

With the arrival of the precision medicine era, tumor risk assessment has gradually come into public view.

Figures show that the survival rate after treatment can be above 70 percent when the tumor is found in the early stages, usually in phase 1. The rate will drop to 20 percent when it's found in phase 4.

However, most tumor cases are found in the middle or late stages.

Anpac Bio-Medical Science Co Ltd from the Zhangjiang National Innovation Demonstration Zone in Shanghai is at the frontier of the early tumor testing industry.

Testing technologies developed by the company enable patients to easily detect tumor risks in the early stages.

With 2 milliliters of blood, cancer differentiation analysis technology can detect more than 10 different types of cancer in all stages of development, especially in the earliest stages.

In addition to distinguishing the tumor's likely location in the body, such technology can also help medical staff to identify the specific disease and find the best options for treatment.

"Most people can survive cancer if the disease is caught early," said Yu Chang, chairman of the company. "What we do is to help people to identify tumor risks early rather than confirm the illness or provide treatment."

With a multinational team of medical, biomedical and nanotechnology scientists and engineering experts, the company's cross-disciplinary approach combines medicine, biochemistry, chemistry, materials, fluid mechanics, signal detection and processing, physics, precision machine engineering and software engineering to achieve vastly superior early cancer screening and detection technology.

The company said the CDA technology is far more accurate than other traditional cancer testing methods, with a 75 to 90 percent sensitivity and specificity rate, in over 35,000 cases to date.

With liver, lung and oesophageal cancers, the technology's sensitivity even surpasses those in the United States, a country with the most developed biopharmaceutical industry, according to Anpac.

The company has obtained about 150 patents, more than 80 percent of which are invention patents.

So far, the company has established partnerships with more than 150 hospitals and health check organizations from more than 40 cities in the country.

In addition to building a medical organization system that integrates the functions of hospitals, health check centers and clinical testing, the company has also worked to create high-end health check centers with innovative and unique technology platforms.

With the completion of a nationwide clinical testing network, the company has finished a series of business integrations, including testing platforms and technology innovation, product design, technology development, equipment manufacturing, clinical testing, customer service, medical data and health management, the company said.

"We have been accelerating the building of a tumor risk assessment system based on the CDA technology testing platform, and arranging the layout of featured medial testing items and centers in China and the US," said Yu Chang, chairman of the company.

Yu said in 2017 the company will further promote its strategic layout of a clinical detection network through a variety of business partnerships.